Four start-ups chosen for the B. Braun Accelerator Program
In order to promote innovative company foundations in the medical technology industry and make them available to the Group, the B. Braun Melsungen AG launched the B. Braun Accelerator Program in November 2017. Now the first four start-ups were selected to participate in the program.
The call for tenders has been very well recived, as 172 companies from 40 countries and five continents applied for the Accelerator Program. B. Braun will support the four start-ups which convinced the jury at the final “speed pitching“ in Melsungen with their short presentations with individually tailored measures, thereby enabling them to quicker transform their ideas into business models.
“By cooperating with the start-ups, we gain insights into future trends and access to external innovations, new business areas and refreshing methods,” says Alexander Katzung, Vice President Acceleration & Innovation. “This complements and extends the innovative ideas of our employees, which we also want to promote with the B. Braun Accelerator in the future“.
The four selected start-ups are passionate about driving innovations in a variety of different areas. BOCA Health (Milan/Berlin) developed a system that allows dialysis patients to monitor their total body water level via smartphone, thus giving them the opportunity to counter dangerous overhydration or dehydration in a timely manner. Bluedrop Medical from Galway, Ireland has the objective to better predict and therefore significantly reduce the risk of diabetic foot ulcers that, in the worst case, could lead to amputation: With a simple device that can be used at home, diabetics take a daily, ten-second scan of their feet. The data is then analyzed via internet and, if necessary, the alarm is sounded.
Admetsys from Boston (USA) has taken on the problem of one’s post-operative blood sugar level, which always has to be laboriously brought back into balance. Until now, this has always taken place through tedious manual controls and treatments. A system developed by Admetsys measures the blood values and fully automatically doses the insulin. Finally, Recare from Berlin uses artificial intelligence for efficient Discharge Management in clinics: if the social service completes an anonymous, digital transition questionnaire for a patient, the software automatically finds suitable providers for the follow-up care.
These start-ups will now be supported by B. Braun for six months with access to various resources. Experts and mentors from different departments of the Group will advise the company founders, who will also be provided with a work environment.